Home | Structured Search | Drug Resource
Find: within
Gout > Follow-up Author: Grace P. Teal, MD; Howard A. Fuchs, MD
Editorial changes - 2009-09-02
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up
Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Uric acid levels should generally be <6 mg/dL for effective management.
  • Uric acid levels will reach steady state about 2 weeks after uric acid-lowering medications are instituted or changed.

Evidence:

  • A retrospective study discusses the optimal range of serum urate concentrations to minimize risk for gout attacks during antihyperuricemic treatment (54).
  • A controlled clinical trial compared treatment with allopurinol and probenecid (75).

Comments:

  • None.
FAQs
Grace P. Teal, MD (deceased) has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Howard A. Fuchs, MD, is a consultant for TAP Pharmaceuticals.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.